Replimune Group (NASDAQ:REPL – Get Free Report) and MiNK Therapeutics (NASDAQ:INKT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends. Insider and Institutional Ownership 92.5% of Replimune […]